Page 675«..1020..674675676677..680690..»

Synthetic Stem Cells Market 2021 Briefing, Trends, Applications, Types, Research, Forecast To 2028 – The Market Writeuo – The Market Writeuo

Posted: August 18, 2021 at 2:00 am

A new market study is released on Synthetic Stem Cells Market with data Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. Research report performs the methodical and comprehensive market research study that puts forth the facts and figures linked with any subject about industry. It all-inclusively estimates general market conditions, the growth prospects in the market, possible restrictions, significant industry trends, market size, market share, sales volume and future trends. A team of skilled analysts, statisticians, research experts, enthusiastic forecasters, and economists work painstakingly to structure such a great market report for the businesses seeking a potential growth. A worldwide analysis report is generated with the best and advanced tools of collecting, recording, estimating, and analyzing market data.

Major insights of the realistic Synthetic Stem Cells Market report are complete and distinct analysis of the market drivers and restraints, major market players involved like industry, detailed analysis of the market segmentation and competitive analysis of the key players involved. Market segmentation categorizes the market depending upon application, vertical, deployment model, end-user, and geography etc. This global market document also presents an idea about consumers demands, preferences, and their altering likings about particular product. Furthermore, big sample sizes have been utilized for the data collection in the winning Synthetic Stem Cells Market report which suits the necessities of small, medium, as well as large size of businesses.

Synthetic stem cells market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to USD 54.25 million by 2028 growing at a CAGR of 15.44% in the above-mentioned forecast period. The growing awareness amongst the physicians and patients regarding the benefits of synthetic stem cells which will further create lucrative opportunities for the growth of the market.

Download Exclusive Sample Report (350 Pages PDF with All Related Graphs & Charts) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-synthetic-stem-cells-market

The major players covered in the synthetic stem cells market report are North Carolina State University (NCSU); Zhengzhou University; among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Competitive Landscape and Synthetic Stem Cells Market Share Analysis

Synthetic stem cells market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to synthetic stem cells market.

The synthetic stem cells are very fragile and prior to use require careful storage, typing, and characterization. In somewhat similar ways to that of deactivated vaccines, the synthetic stem cells function. The membranes of the synthetic stem cells let the immune response bypass them. Synthetic stem cells cant amplify themselves, though.

Growing number of ethical concerns regarding embryonic stem cells, rising risk of tumor formation andimmunerejection of natural stem cells, surging volume of patients suffering from cardiovascular disorders across the globe, generalization of technology to different stem cell types and better preservation stability, rise in stem-cell targeted therapies in neurology and cardiology for research activities are some of the major as well as vital factors which will likely to augment the growth of the synthetic stem cells market in the projected timeframe of 2021-2028. On the other hand, growing number of applications in major indication, surging levels of investment for research activities along with costlystorageand fragility of natural stem cells which will further contribute by generating massive opportunities that will lead to the growth of the synthetic stem cells market in the above mentioned projected timeframe.

For More Insights Get FREE Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-synthetic-stem-cells-market

Unclear and unstructured regulations on the use of product along with lack of skilled professionals which will likely to act as market restraints factor for the growth of the synthetic stem cells in the above mentioned projected timeframe. Approvals of synthetic stem cells are still not well-structured which will become the biggest and foremost challenge for the growth of the market.

This synthetic stem cells market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on synthetic stem cells market contact Data Bridge Market Research for anAnalyst Brief,our team will help you take an informed market decision to achieve market growth.

Global Synthetic Stem Cells Market Scope and Market Size

Synthetic stem cells market is segmented on the basis of application and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

TO UNDERSTAND HOW COVID-19 IMPACT IS COVERED IN THIS REPORT GET FREE COVID-19 [emailprotected] https://www.databridgemarketresearch.com/covid-19-impact/global-synthetic-stem-cells-market

Synthetic Stem Cells Market Country Level Analysis

Synthetic stem cells market is analysed and market size insights and trends are provided by country, application and end user as referenced above.

The countries covered in the synthetic stem cells market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the synthetic stem cells market due to the increasing prevalence of target diseases, focus on development of for regenerative medicines, fast adoption of advanced therapies in the region, while Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2021 to 2028 due to the growing trend of synthetic stem cell technology and will be the early adopter of this technology.

The country section of the synthetic stem cells market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Read More @ https://www.databridgemarketresearch.com/reports/global-synthetic-stem-cells-market

Healthcare Infrastructure growth Installed base and New Technology Penetration

Synthetic stem cells market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for synthetic stem cells market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the synthetic stem cells market. The data is available for historic period 2010 to 2019.

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email @[emailprotected]

The rest is here:
Synthetic Stem Cells Market 2021 Briefing, Trends, Applications, Types, Research, Forecast To 2028 - The Market Writeuo - The Market Writeuo

Posted in Stem Cells | Comments Off on Synthetic Stem Cells Market 2021 Briefing, Trends, Applications, Types, Research, Forecast To 2028 – The Market Writeuo – The Market Writeuo

More positive results from CRISPR trial for sickle cell and thalassaemia – BioNews

Posted: August 18, 2021 at 2:00 am

16 August 2021

A genome editing-based gene therapy forblood diseasessickle cell disease andbeta-thalassaemia continues to be effective more than two years after treatment.

The clinical trial for the therapy, named CTX001, previously reported good preliminary results (see BioNews 1052) and new data was presented at the European Haematology Association 2021 Virtual Congress.

'We are hearing that it is life-changing.' said Professor Stephan Grupp from the Cell and Gene Therapy Laboratory at Children's Hospital of Philadelphia, one of the researchers collaborating on the trial.

Patients with sickle cell disease or beta-thalassaemia carry a mutation in a single gene that causes problems in an essential blood molecule called haemoglobin. Patients usually require lifelong blood transfusions, sometimes stem cell transplants, as well as ongoing pain management. Sickle cell disease can also impact reproductive health in women (see BioNews 1105).

This clinical trial involved taking a patient's own blood stem cells, called hematopoietic stem cells, and editing them outside the body.CRISPR/Cas9 genome editing wasused to reactivatea different haemoglobin gene that is usually only expressed in the fetus and is switched off at birth. The editedstem cells were transplanted back into thepatients, who started producing fetal haemoglobin,replacingthe nonfunctional haemoglobin that causeddisease symptoms.

'The data presented today in 22 patients are impressive in both the consistency and durability of effect. These results add to the growing body of evidence that CTX001 may hold the promise for a one-time functional cure for sickle cell disease and beta-thalassemia.' said Dr Reshma Kewalramani, CEO of Vertex Pharmaceuticals in Boston, Massachusetts, who developed the treatment in partnership with CRISPR Therapeutics from Zug, Switzerland.

Aftertwo years post-gene therapy, the sickle cell disease patients were reported to be free of vaso-occlusive crises; a painful organ injury occurring when blood cells cause blockages, common to sickle cell disease patients. None of the beta-thalassaemia patients has required any further blood transfusions as all have started producing functional levels of fetal haemoglobin in their blood.

'The evidence so far indicates that it is durable in the time frame we've seen, and we just have to continue to follow the patients' said Professor Grupp.

The rest is here:
More positive results from CRISPR trial for sickle cell and thalassaemia - BioNews

Posted in Stem Cells | Comments Off on More positive results from CRISPR trial for sickle cell and thalassaemia – BioNews

EDITORIAL: The need is vast. Consider becoming an organ donor. – Yahoo News

Posted: August 18, 2021 at 1:55 am

Aug. 14Post Bulletin reporter Nora Eckert's ongoing series of stories on organ transplants have been shining a light on a critical need in Minnesota and the U.S.

More than 100,000 men, women and children are on the national transplant waiting list, every nine minutes or so another one is added, and on average 17 people die each day waiting for an organ transplant.

Eckert has told us about Ken Hanson, our former work colleague at the Post Bulletin, who waits for a kidney transplant as he is supported by a team of friends and caregivers.

And we have read about Linda and Tom Christopherson, a husband and wife whose transplant story, about the heart-shaped kidney Linda gave to Tom, touched our hearts.

In Rochester, more than 1,000 people wait for a viable organ donor to be found to help them. If you find it in your heart or your kidney, or pancreas to be a donor to help them, here are some things to know. These facts come from the website of the Health Resources and Services Administration, organdonor.gov.

You have to be 18 or older to make yourself a donor, and there's no strict upper age limit, although donors have to be in generally good health to be accepted. Donors under age 18 can do so with permission of a parent or guardian.

Eight vital organs heart, kidneys, pancreas, lungs, liver, intestines, hands, and face can be donated, as can tissue (including corneas), bone marrow and stem cells.

Race is not a factor in matching donors and recipients, but minorities have a higher need for transplants, because some diseases that cause end-stage organ failure are more common in these groups of people.

Having an organ donor card or checking the organ donor box on your driver's license may not be enough to guarantee your organs will be donated. It's necessary to enroll in your state registry, a process that is described at organdonor.gov. It's also a good idea to talk to your family about your intent to donate.

Story continues

If you want to donate your body for scientific research not an uncommon desire in the Med City you might not be able to also donate specific organs. Consult your medical provider to see what may be permitted.

Blood donations also are sorely needed at this time.

You've heard the saying about wealth, "You can't take it with you." Same goes for our body parts that might be used to prolong others' lives. Consider being a donor.

Read more:
EDITORIAL: The need is vast. Consider becoming an organ donor. - Yahoo News

Posted in Minnesota Stem Cells | Comments Off on EDITORIAL: The need is vast. Consider becoming an organ donor. – Yahoo News

Our View: The need is vast. Consider becoming an organ donor. – PostBulletin.com

Posted: August 18, 2021 at 1:55 am

Post Bulletin reporter Nora Eckerts ongoing series of stories on organ transplants have been shining a light on a critical need in Minnesota and the U.S.

More than 100,000 men, women and children are on the national transplant waiting list, every nine minutes or so another one is added, and on average 17 people die each day waiting for an organ transplant.

Eckert has told us about Ken Hanson, our former work colleague at the Post Bulletin, who waits for a kidney transplant as he is supported by a team of friends and caregivers.

And we have read about Linda and Tom Christopherson, a husband and wife whose transplant story, about the heart-shaped kidney Linda gave to Tom, touched our hearts.

In Rochester, more than 1,000 people wait for a viable organ donor to be found to help them. If you find it in your heart -- or your kidney, or pancreas -- to be a donor to help them, here are some things to know. These facts come from the website of the Health Resources and Services Administration, organdonor.gov.

You have to be 18 or older to make yourself a donor, and theres no strict upper age limit, although donors have to be in generally good health to be accepted. Donors under age 18 can do so with permission of a parent or guardian.

Eight vital organs -- heart, kidneys, pancreas, lungs, liver, intestines, hands, and face -- can be donated, as can tissue (including corneas), bone marrow and stem cells.

Race is not a factor in matching donors and recipients, but minorities have a higher need for transplants, because some diseases that cause end-stage organ failure are more common in these groups of people.

Having an organ donor card or checking the organ donor box on your drivers license may not be enough to guarantee your organs will be donated. Its necessary to enroll in your state registry, a process that is described at organdonor.gov. Its also a good idea to talk to your family about your intent to donate.

If you want to donate your body for scientific research -- not an uncommon desire in the Med City -- you might not be able to also donate specific organs. Consult your medical provider to see what may be permitted.

Blood donations also are sorely needed at this time.

Youve heard the saying about wealth, You cant take it with you. Same goes for our body parts that might be used to prolong others lives. Consider being a donor.

Read more here:
Our View: The need is vast. Consider becoming an organ donor. - PostBulletin.com

Posted in Minnesota Stem Cells | Comments Off on Our View: The need is vast. Consider becoming an organ donor. – PostBulletin.com

Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy…

Posted: August 18, 2021 at 1:53 am

DetailsCategory: DNA RNA and CellsPublished on Monday, 16 August 2021 17:11Hits: 496

LA JOLLA, CA, USA I August 16, 2021 I Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company with novel allogeneic stem cell platforms for delivery of oncolytic viruses, together with the University of Chicago and City of Hope, a world renowned NCI-Designated Comprehensive Cancer Center, based in Duarte, California, have entered into an exclusive worldwide licensing agreement for patents covering cutting edge therapies using an oncolytic adenovirus in combination with a clinical grade allogeneic neural stem cell line.

City of Hope (COH) scientists, led by Dr. Karen Aboody in collaboration with Dr. Maciej Lesniak's team at University of Chicago, and later Northwestern University, have used COHs exclusive GMP grade immortalized, clonal human neural stem cell line, to selectively deliver an oncolytic adenovirus to tumor sites. Dr. Aboody and Dr. Lesniak, together with Dr. Rachael Mooney at COH, have spent 13 years in a passionate effort to translate promising pre-clinical results into the clinic, attaining FDA approval for commencing a first-in-human Phase-1 trial in recurrent glioma patients.

We are very excited about the partnership and collaboration with Calidi Biotherapeutics. Their deep understanding and expertise using allogeneic stem cells as a delivery platform to protect, deliver, amplify, and potentiate oncolytic virotherapy, can potentially result in a significantly more effective treatment for cancer patients with invasive tumors, commented Dr. Karen Aboody, Professor, Department of Developmental and Stem Cell Biology, City of Hope National Medical Center & Beckman Research Institute.

The first wave of Oncolytic Viruses were novel, but lacked the ability to efficiently deliver the virus to tumor sites, due to the human complement immune system inactivating the viruses, usually within one hour of patient injection, thus resulting in a lack of efficacy, stated Allan Camaisa, Co-Founder, Chairman and CEO of Calidi Biotherapeutics. We believe this collaboration with City of Hope will allow us to implement Calidis proprietary techniques together with City of Hopes novel approach to glioblastoma and other malignant tumors, using neural stem cells combined with an oncolytic adenovirus. This FDA approved Investigational New Drug (IND), planned for patient trials in the first quarter of 2022, increases Calidis drug pipeline and gives our company a tumor-tropic stem cell line to use for oncolytic virus delivery in cancer patients.

This exclusive license agreement, which was executed by the University of Chicagos Polsky Center for Entrepeneurship and Innovation, transferred the COH/University of Chicago IND to Calidi for the commercial development of a licensed product. The agreement grants to Calidi commercial exclusivity in using neural stem cells with the adenovirus known as CRAd-pk-S-7 for oncolytic virotherapy.

Calidis scientific and medical teams are very excited to contribute in the development of this promising technology that has significant potential to help many patients with advanced tumors, said Boris Minev, MD, President, Medical and Scientific Affairs at Calidi Biotherapeutics. We are delighted to collaborate with the outstanding researchers and clinicians who developed this novel oncolytic virotherapy approach.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses protected by stem cells for targeted therapy against difficult-to-treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidis off-the-shelf, universal cell-based delivery platform is designed to protect, amplify, and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit http://www.calidibio.com.

About University of Chicago

The University of Chicago is a leading academic and research institution that has driven new ways of thinking since its founding in 1890. As an intellectual destination, the University draws scholars and students from around the world to its campuses and centers around the globe. The University provides a distinctive educational experience and research environment, empowering individuals to challenge conventional thinking and pursue field-defining research that produces new understanding and breakthroughs with global impact.

The Polsky Center for Entrepreneurship and Innovation applies world-class business expertise from the University of Chicago Booth School of Business to bring new ideas and breakthrough innovations to market. Home of the Universitys technology transfer office, the Polsky Centers dedicated team of professionals with deep technical expertise enabling technology commercialization perform market analysis, manage intellectual property, identify partners, and negotiate partnerships and licenses for discoveries and inventions developed by faculty, researchers, and staff. Learn more at polsky.uchicago.edu and follow us on Twitter @polskycenter.

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies, and numerous breakthrough cancer drugs are based on technology developed at the institution. Translational Genomic research (TGen) became a part of City of Hope in 2016. AccessHope, a wholly owned subsidiary, was launched in 2019, dedicated to serving employers and their health care partners by providing access to City of Hopes exceptional cancer expertise. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nations Best Hospitals by U.S. News & World Report. Its main campus is located in Pasadena, California, near Los Angeles, with additional locations throughout Southern California and in Arizona. For more information about City of Hope, follow us on Facebook, Twitter, YouTube, or Instagram.

SOURCE: Calidi Biotherapeutics

More here:
Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy...

Posted in Arizona Stem Cells | Comments Off on Calidi Biotherapeutics Announces Exclusive License Agreement with City of Hope and the University of Chicago for Novel Oncolytic Virotherapy…

Dont ignore those stomach woes – The New Indian Express

Posted: August 18, 2021 at 1:52 am

Express News Service

BENGALURU:Almost everyone has experienced pain in the stomach at some point of time or the other. Whether from eating too much junk food or acquiring virus, we all know what it is like to suddenly be affected with stomach problems. Its also understood that not all stomach pain is the same. Stomach is an important part of the human body and is significantly linked to overall health and disease.

Stomach pain could be a sign of a wide range of health issues, and this could also be due to multiple reasons and can be the cause of concern if it continues. It could be due to a simple infection or development of cancerous cell in the stomach. Hence such pain should never be neglected.

Stomach cancer mostly affects the elderly and two-thirds of those who have it are over the age of 65. It is an abnormal growth of cells that begins in the stomach and spread to other organs of the body like the liver, lungs, and bones. Since stomach cancer usually doesnt cause any early symptoms, it often goes undiagnosed until it spreads to other parts of the body. Weight loss and continued abdominal pain are the most common symptoms at initial diagnosis.

Stomach cancer typically begins as precancerous that can develop into cancer slowly over time. Though some of these changes are evident in diagnostic procedures such as endoscopy, they usually dont cause any symptoms until the cancer progresses. The symptoms include:

Although genetic predisposition can impact the risk of developing stomach cancer, certain lifestyle factors also play a key role. One may be more likely to be diagnosed with stomach cancer if you consume a lot of processed foods and meat and are obese. Lifestyle changes like losing weight, avoiding large meals, reducing the intake of salty and processed foods, following a diet rich in fruits, vegetables, lean proteins and avoiding tobacco use can help in decreasing the risk of stomach cancer.

TreatmentTreatment depends upon the stage of tumour and fitness of the patient to undergo surgical procedure. Treatment can be broadly categorised into curative and palliative. Curative treatment intends to eradicate the disease. To get the best results in advanced tumours, chemotherapy, radiotherapy, and surgery are combined in an approach called multimodal treatment. Depending upon the extent of tumour, chemotherapy can be given before surgery or after surgery.

Suffering from indigestion or heartburn after a meal doesnt mean you have cancer. But if symptoms persist or gets worse, it is better to consult your health care professional and get checked immediately.

(The writer is a consultant surgical oncology, HCG Cancer Hospital Bengaluru)

Excerpt from:
Dont ignore those stomach woes - The New Indian Express

Posted in HCG Diet | Comments Off on Dont ignore those stomach woes – The New Indian Express

People and places at Penn | Penn Today – Penn Today – Penn Today

Posted: August 18, 2021 at 1:51 am

For many students, attending college marks the first time away from home, the first time managing a budget, even the first time doing laundry. New spaces, new classes, new friends, new routines. This year, its not just new for the freshmen. For many, late August will mark their first return to campus since March 2019. In anticipation of Move-In, Penn Today asked six undergraduate students in the Philadelphia area this summer to divulge their favorite spots.

Ariana Jimnez found her niche on an exploratory walk, while Steven Chen and Quinn Gruber found theirs through special interests, and Lucas Monroe gravitates to athletic history. Francisco Barrera chose a study spaceand where he goes to decompress. Dorms, libraries, and outside spaces are all on the list. Morgan Bacon is most looking forward to Hey Day to kick off this semester. Its nerve-wracking to be declared a senior, but also very exciting. Ive enjoyed my time at Penn so much, she says. I can't wait to reconnect with my friends and just hang out on the grass.

Steven Chens first engagement with Penn was through the Netter Center for Community Partnerships, and as aPenn Program for Public Service intern, the biology major from Warminster, Pennsylvania now works through Netter Centers OurSpace to host weekly meetings with a group of West Philadelphia and Penn students at the LGBT Center, one of his favorite campus spots. Its a very accepting space, Chen says, a place for them to have fun and express themselves.

The sophomore is currently collaborating with the LGBT Center and the Netter Center to develop aqueer sexual health education program that utilizes peer-assisted learning. A pre-med student, Chen is interested in providing health care access to queer people and people of color. You have to be healthy to pursue your other dreams, he says. Health is the foundation.

I like a good puzzle or challenge, says Ariana Jimnez, who plans to investigate white-collar crime as an FBI agent. This requires business-industry experience, so the sophomore from Plainfield, Illinois is enrolled in the Wharton School, concentrating on finance and social impact.

She passed the benches in the engineering quad on a walk one day, and which has since become a favorite place to chill and listen to music, Jimnez says. Currently Im bingeing Taylor Swift before her new album comes out.

Jimnez is looking forward to having the opportunity to engage with people face-to-face this fall, she says. Shes also looking forward to living in New College House West. You already know Im going to be exploring that as soon as I get in there, she says. While on routine walks, Im always trying to look in to see if it looks cool, Jimnez says. And it does look cool.

Francisco Barrera of Miami, Florida is really interested in the energy problem. Barrera wants to part of the solution, so he applied to Penns Vagelos Integrated Program in Energy Research, where the senior is studying engineering and physics. Barrera spent his summer doing research with Deep Jariwala of the Device Research and Engineering Laboratory, looking into new materials and new configurations for maximizing light absorbance and efficiency for the next generation of solar cells, he says.

Barreras favorite place to study is the Fisher Fine Arts Library. Im always surrounded by STEM. The Fine Arts Library is a little bit of an escape from that, he says. I was always totally inspired by how beautiful the inside was. Its so quiet compared to other study spaces.

When not working, Barrera heads to the beach volleyball court, a great stress reliever, he says, especially during freshman year when the Miami student was adjusting to college life. The sandy court makes it more fun and athletic, Barrera says, Im more willing to throw myself down to dive for a ball.

A double major in English and Italian from Cortlandt Manor, New York, Quinn Gruber loves the Student Projects Space at the Kelly Writers House. The space is special for me because its the home of the Zine Library, a student-run collection of zines (small, self-published books/pamphlets/print objects) that Ive helped curate for three years now, with Alyson del Pino (C21) and now Victoria Garcia (C23), says Gruber, currently a senior. I love hanging out on the green beanbag with a hot cup of tea and reading the amazing zines that we have in the library, and appreciate the space as a great resource for students who make art,since we have supplies,books, and printing available for everybody.

Gruber also plays violin in a Penn Chamber Quartet, an important reprieve from the pressures of work and school, they say. Gruber enjoys visiting the Eugene Ormandy Music & Media Center to borrow whatever piece Im working on, whether for Chamber or myself, and to discover new music by just wandering through the stacks, they say.

I was always really passionate about nutrition, and more specifically childhood nutrition, says Morgan Bacon. Growing up in Philadelphia, Bacon was acutely aware of food deserts, and began working with the Food Trust. Along with social determinants, she realized how big of a role nutrition played in heath, and applied to Penn Nursing.

The Annenberg Center is one of Bacons favorite places, because the senior attended a performing arts camp here as a child, which piqued my interest in college, she says. It all seemed like a glamorous life.

Once on campus, Bacon spent two years living at Lauder College House. I just loved it so much, she says. The courtyard area was a space where the house could come together.

Im on the basketball team, so thats an easy choice for me, says Lucas Monroe of Abington, Pennsylvania, of why he chose the Palestra as one of his favorite campus spots. But Im also a huge basketball nerd and the Palestra is the cathedral. Its Mecca. More games have been played there than in any other college arena, and thats why its so historic. I like to sit at the top, he says. Ill do homework up there; Ill read up there.

Monroe, a junior majoring in political science with a minor in Africana Studies, also likes to work on the hill outside of Van Pelt-Dietrich Library. Its a peaceful spot, he says, but also one thats good for people watching. You have the library to the left of you, College Hall diagonal. The Franklin statue and the Button are all right there; theres a lot of cool things you can look at.

Homepage image: Clockwise from top left: Morgan Bacon, Ariana Jimnez, Francisco Barrera,Quinn Gruber, Lucas Monroe, and Stephen Chen introduce their favorite places at Penn.

Follow this link:
People and places at Penn | Penn Today - Penn Today - Penn Today

Posted in Pennsylvania Stem Cells | Comments Off on People and places at Penn | Penn Today – Penn Today – Penn Today

FDA Puts APB-102 Gene Therapy for SOD1 ALS on Fast Track – ALS News Today

Posted: August 5, 2021 at 2:51 am

The U.S. Food and Drug Administration (FDA) has granted fast track status to Apic Bios experimental therapy APB-102, designed for amyotrophic lateral sclerosis (ALS) patients who carry mutations in the SOD1 gene that lead to misfolded proteins in cells.

This designation accelerates the development of investigational therapies that address unmet medical needs in serious or life-threatening conditions. It makes Apic Bio eligible for more frequent meetings with the FDA and discussions about APB-102s development plan.

We are pleased that the FDA recognizes the significant unmet need for treatments for SOD1 ALS, an always fatal neurogenerative disorder, where mutations in the SOD1 gene account for approximately one-fifth of all inherited forms of the disease, Jorge Quiroz, MD, executive vice president and chief medical officer of Apic Bio, said in a press release.

About 1520% of people with familial ALS and 12% of those with sporadic ALS carry mutations in the SOD1 gene. These mutations result in the production of neurotoxic forms of the SOD1 protein, an enzyme responsible for the removal of free radicals, which is important for cellular health.

APB-102 is a gene therapy designed to address ALS cases caused by SOD1 mutations. It consists of a microRNA a small RNA molecule that latches onto intermediate RNAs carrying the genetic instructions for protein production that binds to a certain portion of the SOD1 RNA sequence and prevents the SOD1 protein from being produced.

This microRNA molecule is contained inside a harmless adeno-associated virus and delivered into the spinal canal via a direct (intrathecal) injection. In a proof-of-concept study involving two ALS patients, APB-102 lowered SOD1 levels in their brain and spinal cord.

The FDA recently cleared a Phase 1/2 clinical trial to investigate APB-102s safety, tolerability, and efficacy in ALS patients with SOD1 mutations. The study is scheduled to begin early next year, and will be conducted in three parts.

In part 1, study participants will receive single but ascending doses of APB-102 to determine an optimal treatment dose. In the second part, patients will be randomly assigned to receive either a placebo or APB-102, at the dose determined in part 1. Part 3 will consist of an extended follow-up.

APB-102 received orphan drug status from the FDA in July 2019, a designation intended to promote the development of investigational therapies for rare and serious diseases. It offers several benefits, including exemption from FDA application fees and seven years of market exclusivity upon approval.

We believe in the therapeutic potential of our gene therapy candidate APB-102 that targets the underlying pathophysiology of the disease, and we remain on track to initiate our Phase 1/2 study of APB-102 in early 2022, said Quiroz.

Here is the original post:
FDA Puts APB-102 Gene Therapy for SOD1 ALS on Fast Track - ALS News Today

Posted in Uncategorized, Gene therapy | Comments Off on FDA Puts APB-102 Gene Therapy for SOD1 ALS on Fast Track – ALS News Today

Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference – Yahoo Finance

Posted: August 5, 2021 at 2:51 am

NOVATO, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer and President will participate in a panel titled Miss Con-GENE-iality - Updates in Gene Tx on Wednesday, August 11, 2021 at the Wedbush PacGrow Healthcare Conference at 12:00 PM ET.

The live and archived webcast of the presentation will be accessible from the companys website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.

About Ultragenyx Pharmaceutical Inc.

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyxs strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: http://www.ultragenyx.com.

Contact Ultragenyx Pharmaceutical Inc.Investors & MediaJoshua Higa415-475-6370

Read the rest here:
Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference - Yahoo Finance

Posted in Gene therapy | Comments Off on Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference – Yahoo Finance

Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B By 2028 – Contract Pharma

Posted: August 5, 2021 at 2:51 am

According to ResearchAndMarkets.com's new report, Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report by Therapy Type, by Scale (R&D, Commercial), by Mode, by Workflow (Vector Production, Cell Banking), by Region, and Segment Forecasts, 2021 - 2028", the global cell and gene therapy manufacturing market size is expected to reach $57.4 billion by 2028.The market is estimated to grow at a CAGR of 20.3% from 2021 to 2028 due to an exponential rise in clinical pipeline along with a rising number of regulatory approvals for advanced therapies.With this growth are promising opportunities for contract development of cell and gene therapies. Sponsors are forming strategic alliances with contract manufacturers to help accelerate R&D of their candidate programs, increasing demand for CMOs/CDMOs services.Several new methods are being introduced to help advance cell and gene therapy manufacturing, including the potential of single-use technology in production workflows. This method is increasingly gaining attention to help speed the development process while reducing the overall cost and production timeline. Such technological advancements are expected to further drive market growth over the next few years.

View post:
Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B By 2028 - Contract Pharma

Posted in Gene therapy | Comments Off on Global Cell & Gene Therapy Mfg. Market Could Reach $57.4B By 2028 – Contract Pharma

Page 675«..1020..674675676677..680690..»